Stella Diagnostics Inc.
SLDX
Other OTC0.01
USD
- -
- -
Stella Diagnostics Inc.
SLDX
(Other OTC)
Recent
price
0.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Stella Diagnostics, Inc. (SLDX) operates as a molecular diagnostics company focused on developing advanced tools and drug targets for esophageal diseases, including gastroesophageal reflux disease (GERD), Barrett's esophagus, and esophageal cancer; its core offerings center on targeted mass spectrometry-based proteomic assays such as STLA101 (also known as BE-Smart), which analyzes tissue from the lower esophagus to assess disease progression risk and identify high-risk patients for precancerous or cancerous transformation, providing actionable insights to gastroenterologists, surgical oncologists, and pathologists. The company targets the management of severe esophageal conditions affecting over 67 million patients primarily in the United States, with operations based out of its headquarters at 50 West Broadway, Suite 300, Salt Lake City, Utah; founded in 1992 by Fred Zaino and Joe Abdo (with key development starting around 2020), it trades on the OTC Pink Sheets market. Recent major developments include the January 2023 asset sale to ProPhase Labs, Inc., under which ProPhase acquired worldwide rights to the BE-Smart test and related intellectual property for approximately $4.6 million in cash and stock (plus potential milestone payments and royalties), following earlier optimizations of the STLA101 panel in partnership with mProbe, Inc., collaborative research with institutions like Mayo Clinic and Kansas University Medical Center, and a 2021 name change from JMD Properties, Inc.
Stella Diagnostics and Mayo Clinic to Present Data on the Utility of the STLA101 Test for Esophageal Cancer Staging at the 2022 AGA Digestive Disease Week Conference
Stella Diagnostics to Present at “Next Big Thing” Session at Society of American Gastroenterologists and Endoscopic Surgeons Annual Meeting